Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease-Reference-Cited by-同舟云学术

Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease

Author:

Retout Sylvie¹,Gieschke Ronald¹,Serafin Daniel¹,Weber Cornelia¹,Frey Nicolas¹,Hofmann Carsten¹

Affiliation:

1. Roche Pharma Research and Early DevelopmentPharmaceutical SciencesClinical PharmacologyRoche Innovation Center Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference22 articles.

1. World Health Organization (WHO).Dementia fact sheet. Accessed September 29 2020.

2. World Health Organization (WHO).The top 10 causes of death. Accessed September 29 2020.

4. US Food and Drug Administration.FDA Grants Accelerated Approval for Alzheimer’s Drug (2021).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献